Literature DB >> 12475192

Valproic acid toxicity: overview and management.

Matthew D Sztajnkrycer1.   

Abstract

Acute valproic acid intoxication is an increasing problem, accounting for more than 5000 calls to the American Association of Poison Control Centers in 2000. The purpose of this paper is to review the pharmacology and toxicology of valproic acid toxicity. Unlike earlier antiepileptic agents, valproic acid appears to function neither through sodium channel inhibition nor through direct gamma-aminobutyric acid agonism, but through an indirect increase in regional brain gamma-aminobutyric acid levels. Manifestations of acute valproic acid toxicity are myriad, and reflect both exaggerated therapeutic effect and impaired intermediary metabolism. Central nervous system depression is the most common finding noted in overdose, and may progress to coma and respiratory depression. Cerebral edema has also been observed. Although hepatotoxicity is rare in the acute overdose setting, pancreatitis and hyperammonemia have been reported. Metabolic and hematologic derangements have also been described. Management of acute valproic acid ingestion requires supportive care and close attention to the airway. The use of controversial adjunctive therapies, including extracorporeal drug elimination and L-carnitine supplementation, will be discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12475192     DOI: 10.1081/clt-120014645

Source DB:  PubMed          Journal:  J Toxicol Clin Toxicol        ISSN: 0731-3810


  42 in total

1.  Case files of the Children's Hospital of Michigan Regional Poison Control Center: the use of carnitine for the management of acute valproic acid toxicity.

Authors:  Abhishek Katiyar; Cynthia Aaron
Journal:  J Med Toxicol       Date:  2007-09

Review 2.  Valproic acid-induced hyperammonemic encephalopathy in a full-term neonate: a brief review and case report.

Authors:  Pavla Pokorná; Karolina Hronová; Martin Šíma; Ondřej Slanař; Petr Klement; John N van den Anker; Dick Tibboel
Journal:  Eur J Clin Pharmacol       Date:  2017-02-06       Impact factor: 2.953

Review 3.  Creating a "Prosurvival Phenotype" Through Histone Deacetylase Inhibition: Past, Present, and Future.

Authors:  Ihab Halaweish; Vahagn Nikolian; Patrick Georgoff; Yongqing Li; Hasan B Alam
Journal:  Shock       Date:  2015-08       Impact factor: 3.454

4.  Case Files of the University of California, San Francisco Medical Toxicology Fellowship: Seizures and a Persistent Anion Gap Metabolic Acidosis.

Authors:  Ann Arens; Craig Smollin
Journal:  J Med Toxicol       Date:  2016-04-14

5.  Extracorporeal elimination in acute valproate intoxication.

Authors:  Els A van der Wouden; Angela Dekkers; Hannah M E Kruis; Ingeborg M van Geijlswijk; David H Tjan; Geert W Feith
Journal:  BMJ Case Rep       Date:  2009-02-02

6.  Acute liver impairment after sodium valproate overdose.

Authors:  William Stephen Waring; Andrew C Nixon
Journal:  BMJ Case Rep       Date:  2009-05-11

7.  Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation.

Authors:  Patrick T Grogan; Jann N Sarkaria; Barbara N Timmermann; Mark S Cohen
Journal:  Invest New Drugs       Date:  2014-04-10       Impact factor: 3.850

8.  Valproic acid-associated acute liver failure in children: case report and analysis of liver transplantation outcomes in the United States.

Authors:  Ayse L Mindikoglu; Dale King; Laurence S Magder; John A Ozolek; George V Mazariegos; Benjamin L Shneider
Journal:  J Pediatr       Date:  2010-12-16       Impact factor: 4.406

9.  Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report.

Authors:  Jack M Su; Xiao-Nan Li; Patrick Thompson; Ching-Nan Ou; Ashish M Ingle; Heidi Russell; Ching C Lau; Peter C Adamson; Susan M Blaney
Journal:  Clin Cancer Res       Date:  2010-11-29       Impact factor: 12.531

Review 10.  The Role of RRT in Hyperammonemic Patients.

Authors:  Shruti Gupta; Andrew Z Fenves; Robert Hootkins
Journal:  Clin J Am Soc Nephrol       Date:  2016-05-19       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.